JY232 CAR-T cell therapy for relapsed multiple myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests an investigational CAR-T cell therapy called JY232 for people with multiple myeloma that has returned or not responded to at least two prior treatments. The therapy targets a protein called BCMA on myeloma cells to help your immune system fight the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age between 18 and 75 years old
- Diagnosed with active multiple myeloma that has come back or not responded to past treatments
- Your myeloma cells must test positive for a marker called BCMA
- You must have tried at least two different types of previous myeloma therapy
- Your blood counts, kidney function, and heart function must be within safe limits
- You cannot have serious infections, other cancers, or central nervous system involvement
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental cell therapy called CBG002 CAR-T for people with multiple myeloma that has come back or not responded to standard treatments. The therapy uses your own immune cells that are trained to find and attack myeloma cells with a protein called BCMA on their surface.
This trial tests a new treatment called CAR-T cell therapy for people with multiple myeloma that has come back or not responded to other treatments. The treatment uses your own immune cells, modified in a lab to attack the cancer, and may be an option after a stem cell transplant has not worked.
This Phase 1/2 study tests a personalized CAR-T cell treatment that targets a protein called BCMA on myeloma cells. It’s designed for people with multiple myeloma who have already tried several other treatments and still have measurable disease.
This study tests a new type of cell therapy called BCMA-GPRC5D CAR-T for people whose multiple myeloma has come back or not responded to standard treatments. The therapy uses your own immune cells, modified in a lab, to find and attack myeloma cells.
This early trial tests a new CAR-T cell treatment targeting three proteins (CD19, CD22, and BCMA) on myeloma cells. It's for people whose myeloma came back or didn't respond to at least three prior treatments.
This trial tests a new type of immunotherapy called CAR-T cells that target two proteins (BCMA and FcRL5) on myeloma cells. It is for people whose myeloma has returned or not responded to other treatments.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.